ArticleFoods (Basel, Switzerland)2026
Chinese Yam Polysaccharide Alleviates DSS-Induced Ulcerative Colitis After Antibiotic Pretreatment.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study investigated whether the therapeutic efficacy of Chinese yam polysaccharide (CYP) against ulcerative colitis (UC) depends on an intact gut microbiota. A dextran sulfate sodium (DSS)-induced colitis mouse model was established, and one treatment group received broad-spectrum antibiotics (ABXs) before CYP administration to deplete the intestinal microbiota. CYP markedly attenuated colonic injury, reduced disease activity, and suppressed inflammatory mediators under both microbiota-intact and microbiota-depleted conditions. CYP also enhanced intestinal barrier integrity, as evidenced by reduced serum endotoxin levels and increased expression of MUC-2, Claudin-1, Occludin, and ZO-1. In addition, CYP improved hepatic antioxidant status by increasing GSH-Px and catalase activities and decreasing malondialdehyde levels. Moreover, CYP reduced the activation of the NF-κB and MAPK signaling pathways, with similar trends observed under microbiota-depleted conditions. Microbiota profiling showed that CYP partially corrected DSS-induced dysbiosis, whereas the ABX + CYP group exhibited distinct microbial patterns with enrichment of carbohydrate-related metabolic pathways predicted by PICRUSt2. Collectively, these findings suggest that CYP retains protective efficacy after antibiotic pretreatment, indicating that its effects may not be exclusively dependent on gut microbiota modulation, possibly involving direct actions on immune and intestinal epithelial cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.